Abstract
Introduction
Therapeutic approaches for psoriatic arthritis (PsA) include non-pharmacologic therapies, symptomatic treatments, tumor necrosis factor inhibitors, interleukin inhibitors, cytotoxic T lymphocyte antigen 4 immunoglobulin, and Janus kinase inhibitors. This systematic review aimed to provide complete and up-to-date information on efficacy of tofacitinib in the treatment of PsA, giving special attention to non-skin manifestations (peripheral arthritis, axial disease, enthesitis, and dactylitis).
Methods
A search of studies published between January 2016 and June 2020 was carried out on PubMed and Google Scholar.
Results
The number of studies with tofacitinib in PsA is limited and most of them are post hoc analyses from OPAL Broaden and OPAL Beyond. Tofacitinib has been demonstrated to be efficacious for the treatment of all disease manifestations in PsA. Superior effectivity to placebo is achieved at the earliest time point evaluated, and maintained over time. Patients who switch from placebo to tofacitinib show the same improvements; however, the time to initial response is faster in patients who firstly receive tofacitinib, compared with those switching subsequently. Additional data suggest that tofacitinib may be also effective for the treatment of the axial domain.
Conclusions
Tofacitinib has been demonstrated to be efficacious for the treatment of peripheral and axial involvement, enthesitis, and dactylitis manifestation in PsA. Further prospective and long-term studies are required to corroborate and complete the present results. Similarly, real-world evidence is also necessary to complement the information obtained in clinical trials, and thereby to have a better overview of real efficacy and safety of the drug.
Similar content being viewed by others
References
Gladman DD, Antoni C, Mease P, Clegg D, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(2):14–7.
Mease PJ. Psoriatic arthritis: update on pathophysiology, assessment and management. Ann Rheum Dis. 2011;70(1):77–84.
Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(21):957–70.
Haddad A, Zisman D. Comorbidities in patients with psoriatic arthritis. Rambam Maimonides Med J. 2017;8(1):e0004.
Gudu T, Gossec L. Quality of life in psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(5):405–17.
Gladman DD. Axial disease in psoriatic arthritis. Curr Rheumatol Rep. 2007;9(6):455–60.
Feld J, Chandran V, Haroon N, et al. Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. Nat Rev Rheumatol. 2018;14(6):363–71.
Acosta Felquer ML, Oliver FO. Peripheral joint involvement in psoriatic arthritis patients. Clin Exp Rheumatol. 2015;33(93):26–30.
Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, Ballina Garcia J, Riestra Noriega JL, Lopez LC. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol. 1991;30(4):245–50.
Álvarez Castro C, Zapico Fernández I. Artritis psoriásica: manifestaciones clínicas, diagnóstico, pronóstico. In: Sanmartí Sala R, director. Espondiloartritis. Monografías SER no. 2. Madrid: Médica Panamericana; 2004, p. 219–30.
Lubrano E. Axial disease. In: FitzGerald O, Gladman D, editors. Oxford textbook of psoriatic arthritis. Oxford: Oxford University Press; 2018.
Caso F, Navarini L, Ruscitti P, et al. Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art. Expert Opin Pharmacother. 2020;21(7):785–96.
Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. Arthritis Care Res (Hoboken). 2019a;71(1):2–29.
Berekmeri A, Mahmood F, Wittmann M, Helliwell P. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(9):719–30.
European Medicines Agency. Summary of opinion (post authorisation). Xeljanz tofacitinib. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/004214/WC500247974.pdf. Accessed 17 Oct 2020.
European Medicines Agency. XELJANZ (Tofacitinib). Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/xeljanz-epar-product-information_en.pdf. Accessed 17 Oct 2020.
Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377(16):1537–50.
Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377(16):1525–36.
Eriksen MB, Frandsen TF. The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review. J Med Libr Assoc. 2018;106(4):420–31.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–12.
Asahina A, Etoh T, Igarashi A, et al. Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: a randomized, double-blind, phase 3 study. J Dermatol. 2016;43(8):869–80.
Strand V, de Vlam K, Covarrubias-Cobos JA, et al. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis: results from two phase 3 studies. Ann Rheum Dis. 2017;76:1335–6.
Bachelez H, Griffiths CEM, Papp K, et al. Effect of tofacitinib on efficacy and patient-reported outcomes in psoriasis patients with baseline psoriatic arthritis: a pooled analysis of 2 phase 3 studies. Arthritis Rheumatol. 2017;69.
van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76(8):1340–7.
Ungprasert P, Erwin PJ, Koster MJ. Indirect comparisons of the efficacy of biological agents in patients with active ankylosing spondylitis: a systematic review and meta-analysis. Clin Rheumatol. 2017;36(7):1569–77.
Behrens F, Gomez-Reino J, Nash P, et al. Impact of baseline demographics, disease activity and concomitant medication on American College of Rheumatology 20 response rate and Health Assessment Questionnaire-Disability Index Score with tofacitinib in active psoriatic arthritis: a pooled subgroup analysis of 2 phase 3 studies. Ann Rheum Dis. 2018;77:1585–6.
Kivitz AJ, FitzGerald O, Nash P, et al. Efficacy of tofacitinib by background methotrexate dose in patients with psoriatic arthritis: a post-hoc analysis of pooled data from 2 phase 3 trials. Ann Rheum Dis. 2018;77:1575.
Burmester G, Rigby WFC, Choy E, et al. Changes in lymphocytes and lymphocyte subsets in tofacitinib-treated patients with psoriatic arthritis. Ann Rheum Dis. 2018;77:1030.
Maksymowych WP, van der Heijde D, Baraliakos X, et al. Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients. Rheumatology (Oxford). 2018;57(8):1390–9.
Helliwell P, Coates LC, FitzGerald O, et al. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. Arthritis Res Ther. 2018;20(1):242.
Nash P, Coates LC, Fleischmann R, et al. Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies. Rheumatol Ther. 2018;5(2):567–82.
Ritchlin C, Giles J, Ogdie A, et al. Tofacitinib in patients with psoriatic arthritis and metabolic syndrome: a post-hoc analysis of phase 3 studies. Ann Rheum Dis. 2018;77:1023.
Gladman DD, Orbai AM, Gomez-Reino J, et al. Network meta-analysis of tofacitinib vs bdmards or apremilast for the treatment of TNF inhibitor-naÏve patients with psoriatic arthritis. Ann Rheum Dis. 2018;77:368–9.
Ogdie A, de Vlam K, Bushmakin AG, et al. Baseline pain severity as a predictor of pain improvement following treatment with tofacitinib in psoriatic arthritis. Ann Rheum Dis. 2019;78:1852–3.
Nash P, Coates L, Mease PJ, et al. Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib + methotrexate: a randomized, placebo-controlled sub-study of OPAL Balance. Arthritis Rheumatol. 2019;71(Suppl.10): 5250–5253. https://doi.org/10.1002/art.41108.
Gladman D, Coates L, Wu J, et al. Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo. Arthritis Rheumatol. 2019;71(Suppl. 10):697–9. https://doi.org/10.1002/art.41108.
Ritchlin C, Ogdie A, Giles J, et al. Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. Arthritis Rheumatol. 2019;71(Suppl. 10):2675–7. https://doi.org/10.1002/art.41108.
Nash P, Greenwald M, Lin LH, et al. The impact of time since first diagnosis on the efficacy and safety of tofacitinib in patients with active psoriatic arthritis. Arthritis Rheumatol. 2019;71(Suppl. 10):2605–8. https://doi.org/10.1002/art.41108.
Citera G, Schneeberger E, Nash P, et al. Comparison of different remission indices in patients with psoriatic arthritis: a post hoc analysis of data from phase 3 tofacitinib studies. Arthritis Rheumatol. 2019;71(Suppl. 10):2585–8. https://doi.org/10.1002/art.4110.
Pham PA, Dressler C, Eisert L, Nast A, Werner RN. Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals. Rheumatol Int. 2019;39(4):605–18.
Strand V, de Vlam K, Covarrubias-Cobos JA, et al. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open. 2019a;5(1):e000806.
Strand V, de Vlam K, Covarrubias-Cobos JA, et al. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. RMD Open. 2019b;5(1):e000808.
Song GG, Lee YH. Comparison of the efficacy and safety of tofacitinib and apremilast in patients with active psoriatic arthritis: a Bayesian network meta-analysis of randomized controlled trials. Clin Drug Investig. 2019;39(5):421–8.
van der Heijde D, Gladman DD, FitzGerald O, et al. Radiographic progression according to baseline C-reactive protein levels and other risk factors in psoriatic arthritis treated with tofacitinib or adalimumab. J Rheumatol. 2019;46(9):1089–96.
Lu C, Wallace BI, Waljee AK, Fu W, Zhang Q, Liu Y. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: a systematic review and network meta-analysis. Semin Arthritis Rheum. 2019;49(3):381–8.
Rigby W, Burmester GR, Fitzgerald O, et al. Changes in key laboratory values with tofacitinib 5 mg bid treatment in patients with psoriatic arthritis and rheumatoid arthritis. Ann Rheum Dis. 2019;78:1682–3.
Deodhar A, Chakravarty SD, Cameron C, et al. A systematic review and network meta-analysis of current and investigational treatments for active ankylosing spondylitis. Clin Rheumatol. 2020;39(8):2307–15.
Ogdie A, de Vlam K, McInnes IB, et al. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. RMD Open. 2020;6:e001042.
Galindez E, Prieto-Peña D, Martín-Varillas JL, et al. Treatment with tofacitinib in refractory psoriatic arthritis. Multicenter study of 87 patients in clinical practice. Ann Rheum Dis. 2020;79:1682.
Dougados M, van der Heijde D, Bingham C, et al. The effect of tofacitinib on residual pain in patients with psoriatic arthritis. Ann Rheum Dis. 2020;79:760–1.
Nash P, Coates LC, Kivitz AJ, et al. Safety and efficacy of tofacitinib in patients with active psoriatic arthritis: interim analysis of OPAL Balance, an open-label, long-term extension study. Rheumatol Ther. 2020;7(3):553–80.
Merola JF, Papp KA, Nash P, et al. Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16433Citations:1.
Korotaeva T, Vorobyova L, Loginova E, et al. Tofacitinib improves disease activity and patient-reported outcomes (PROS) in patients (PTS) with active psoriatic arthritis (PSA) in real clinical practice. Ann Rheum Dis. 2020;79:1729.
Chamurlieva M, Loginova E, Gubar E, Korsakova Y, Glukhova S, Korotaeva T. The contribution of joint symptoms, enthesitis, skin and nail psoriasis (PSO) to minimal disease activity (MDA) achievement in psoriatic arthritis (PSA) patients (PTS). Effect of tofacitinib treatment. Data from real clinical practice. Ann Rheum Dis. 2020;79:1669.
Gubar E, Korotaeva T, Korsakova Y, Loginova E, Karpova P. Effect of tofacitinib treatment on active MRI sacroiliitis and disease activity reduction in psoriatic arthritis patients. Data from clinical practice. Ann Rheum Dis. 2020;79:1162.
Loginova E, Korotaeva T, Gubar E, et al. Comparative effectiveness of tofacitinib (TF) and adalimumab (ADA) in psoriatic arthritis (PSA) patients in real clinical practice. Ann Rheum Dis. 2020;79:1168.
Gubar E, Korotaeva T, Korsakova Y, Loginova E, Glukhova S, Karpova P. Association of active MRI sacroiliitis with dactylitis and work productivity impairment in psoriatic arthritis patients. Positive effects of tofacitinib treatment. Data from clinical practice. Ann Rheum Dis. 2020;79:1162–73.
Tucker LJ, Coates LC, Helliwell PS. Assessing disease activity in psoriatic arthritis: a literature review. Rheumatol Ther. 2019;6(1):23–32.
Mease PJ, Woolley JM, Bitman B, Wang BC, Globe DR, Singh A. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol. 2011;38(11):2461–5.
Mease PJ, Palmer JB, Liu M, et al. Influence of axial involvement on clinical characteristics of psoriatic arthritis: analysis from the Corona Psoriatic Arthritis/Spondyloarthritis Registry. J Rheumatol. 2018;45(10):1389–96.
Singh JA, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019b;71(1):5–32.
Ogdie A, Coates LC, Gladman DD. Treatment guidelines in psoriatic arthritis. Rheumatology (Oxford). 2020;59(1):37–46.
Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–12.
Acknowledgements
Funding
Pfizer S.L.U. has unconditionally financed the execution of this project, including the journal’s Rapid Service fee.
Medical Writing, Editorial and Other Assistance
We would like to thank Susan Ramirez and Noelia Llevat for their work looking over this paper. The authors also express their gratitude to Meisys, for helping with the manuscript writing.
Authorship
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Disclosures
Francisco José Rebollo Laserna and Susana Gómez Castro work for Pfizer S.L.U. Jordi Gratacós Masmitjà and Carlos M. González Fernández have nothing to declare.
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.
Data Availability
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gratacós Masmitjà, J., González Fernández, C.M., Gómez Castro, S. et al. Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review. Adv Ther 38, 868–884 (2021). https://doi.org/10.1007/s12325-020-01585-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-020-01585-7